Through this agreement , Solvay Pharmaceuticals will gain access to HUYA 's comprehensive Chinese molecule portfolio , focusing specifically on compounds in the cardiovascular area . As some of these molecules are already in advanced stages of development in China , the partnership will help Solvay Pharmaceuticals speed up its early discovery activities as well as increase the company 's chances for successfully developing innovative new therapies as safety or efficacy information is already available for some of these molecules .